Latest News From Lumira Ventures

Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

Investigator-initiated trial to evaluate AVID200’s safety, anti-fibrotic activity, and ability to restore hematopoiesis in patients with myelofibrosis AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3, the principal drivers of fibrosis in myelofibrosis and other fibrotic …

Forbius Announces First Patient Dosed in Phase 2a Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

This trial evaluates the efficacy of AVID100 in TNBC patients with EGFR-overexpression 20% of TNBC patients highly overexpress EGFR; there is no approved targeted therapy AVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development, targeting both wild-type …

Bardy Diagnostics™ Announces $35.5M in Series B Funding Round

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, April 16, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has raised $35.5 million in Series B funding, led by River Cities Capital Funds with participation from new investors HealthQuest Capital, Aperture Venture Partners, Aphelion …

Aurinia Pharmaceuticals Inc. Announces New CEO and Board Director and Appoints New Chairman of the Board

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer …

Opsens Q2 2019 Revenues Reach a Record Level

Jennifer Schram Opsens, Portfolio News, Press Release

QUEBEC CITY, April 11, 2019 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) today reported its results for the second quarter of 2019. HIGHLIGHTS Consolidated revenues totaled $7.9M in the second quarter of 2019 compared with $5.4M in the corresponding period in 2018, an increase of $2.5M or …

Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

AVID100 is the only clinical-stage anti-EGFR ADC that targets both wild-type and mutant forms of EGFR with limited off-tumor toxicity due to novel mechanism of action Phase 1 confirmed that AVID100 was well-tolerated and established a recommended phase 2 dose …

Forbius Announces a Clinical Trial Collaboration with the Myeloproliferative Neoplasm Research Consortium to Evaluate AVID200, a Novel TGF-beta Inhibitor, in Myelofibrosis

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

MPN-RC sponsored, NIH-supported Phase 1/2 trial in myelofibrosis to commence imminently TGF-beta is a central driver of bone marrow fibrosis in myelofibrosis AVID200 selectively inhibits TGF-beta 1 & 3, the principal fibrotic TGF-beta isoforms, while sparing TGF-beta 2, a positive …

Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor Best-in-class efficacy and safety potential by selectively targeting principal oncogenic TGF-beta isoforms Reverses immunosuppression and renders tumors sensitive to checkpoint blockade in pre-clinical models Jan. 7, 2019 …